# Research Summary — Bremelanotide (PT-141): RECONNECT, Mechanism, Safety, Telehealth Literature

> Summary of the RECONNECT Phase 3 trials, the MC4R signaling pathway, the integrated safety dataset, and the sexual-medicine telehealth literature supporting remote evaluation for HSDD.

Mechanism, RECONNECT Phase 3 results, integrated safety, and the sexual-medicine telehealth literature.

## DOC.01 // PLAIN BRIEF

In plain terms: bremelanotide works centrally — it switches on brain circuits governing sexual desire, not blood flow. The main human evidence is two identical Phase 3 trials (RECONNECT, 1,267 premenopausal women with HSDD) that showed a real but modest gain in desire and a small drop in the distress low desire causes, both statistically significant. A 52-week extension confirmed the effects held and no new safety signals appeared. A brain-imaging study in 31 women directly showed the compound changes how the brain processes sexual cues. The principal tolerability cost is nausea — about four in ten women over long-term use — plus flushing and headache. Transient blood-pressure increase is documented and shapes the label's contraindication in uncontrolled hypertension. The research page below covers mechanism, trial results, safety signals, and the telehealth-specific clinical literature, with every quantitative claim cited.

## Mechanism — MC4R agonism in the central sexual-response circuit

Bremelanotide is a cyclic heptapeptide lactam analog of alpha-melanocyte-stimulating hormone (alpha-MSH), derived structurally from the earlier research compound melanotan II by removal of a C-terminal amide group. Its molecular formula is C50H68N14O10, with a molecular weight near 1,025 Da [10]. The peptide non-selectively agonizes all five melanocortin receptors (MC1R, MC4R, MC3R, MC5R, MC2R), with binding potency in that descending order per the FDA label [06]. At therapeutic doses, the therapeutically relevant target is MC4R, which is densely expressed in the hypothalamus — particularly in the medial preoptic area (mPOA) — and in limbic structures [09].

The current mechanistic model, developed across preclinical and human pharmacology data, holds that bremelanotide activates MC4R in the mPOA, increases central dopaminergic signaling in circuits associated with sexual desire and arousal, and produces the observed clinical effect on desire-domain endpoints [09]. Unlike phosphodiesterase-5 inhibitors, bremelanotide does not act as a peripheral vasodilator in females; its mechanism is central rather than vascular [09]. A 2025 female Syrian hamster study added a useful negative finding: bremelanotide did not alter MC3R or MC4R expression in the ventral tegmental area or nucleus accumbens, and did not enhance sexual reward in a conditioned place preference paradigm — suggesting that the mesolimbic reward circuit is not the primary site of clinical action and that the mPOA hypothesis remains the leading model [20].

MC1R agonism explains the most distinctive non-CNS side effect: focal hyperpigmentation, reported in approximately 1% of Phase 3 participants and more common with darker skin types and frequent dosing [08].

## RECONNECT — the registrational Phase 3 evidence

Two identical Phase 3 trials, RECONNECT 301 and RECONNECT 302, together formed the basis of the 2019 FDA approval. Each enrolled premenopausal women with acquired, generalized HSDD and randomized them to bremelanotide 1.75 mg subcutaneous as-needed versus placebo for 24 weeks of double-blind treatment [01]. The co-primary endpoints were change from baseline in FSFI-D (the desire domain of the Female Sexual Function Index) and in Item 13 of the FSDS-DAO (a single-item measure of distress specifically about low desire).

Both co-primary endpoints met statistical significance in both studies. Treatment differences vs placebo on FSFI-D were 0.30 in Study 301 (p<0.001) and 0.42 in Study 302 (p<0.001) [01]. The 52-week open-label extension enrolled 684 patients and showed sustained improvements without new safety signals [02]. A 2022 narrative review summarizing the integrated dataset reported responder rates near 58% on the FSFI-D endpoint versus roughly 35% on placebo, and a satisfying-sexual-events change of about +25% versus +10% [13]. A 2019 dose-finding Phase 2b responder analysis confirmed 1.75 mg as the optimal dose balancing efficacy and tolerability across the 0.75, 1.25, and 1.75 mg arms tested [14].

Effect sizes are statistically robust but clinically modest. The published guideline literature — most recently the 5th International Consultation on Sexual Medicine — situates bremelanotide as one option within a stepped-care HSDD algorithm that also includes flibanserin and structured psychological interventions, with moderate evidence support [12].

## Safety — what a remote evaluation must screen

Three safety signals dominate the integrated dataset and shape the clinical evaluation. The first is nausea, occurring in 40.0% of subjects on the 1.75 mg dose and driving roughly 8% of all discontinuations [03]. The second is the transient post-dose blood pressure increase: an ambulatory blood pressure monitoring study in 397 women showed a 2.4–3.2 mmHg rise in systolic blood pressure peaking within four hours and resolving within twelve [05]. The label contraindicates bremelanotide in uncontrolled hypertension or known cardiovascular disease for this reason [06][12]. The third is focal hyperpigmentation of the face, gingiva, or breasts in approximately 1% of trial participants, mediated by MC1R agonism, more common with darker skin types and frequent dosing, and occasionally persistent after discontinuation [08].

A fourth signal — clinically less common but operationally important — is the drug interaction with oral naltrexone. Co-administration reduced naltrexone Cmax by approximately 60% and AUC by approximately 40% via slowed gastric emptying [07]. The label therefore excludes use of bremelanotide in patients taking oral naltrexone for alcohol or opioid use disorder [07]. Telehealth medication reconciliation must capture this.

None of these signals require in-person physical examination to screen. They require: a thorough medication and medical history, a documented blood-pressure reading (self-reported, or measured by the patient with an at-home cuff), a skin-type and dosing-frequency counseling step, and an informed-consent step specific to bremelanotide's known adverse effects [18].

## The sexual-medicine telehealth literature

A small but growing body of practice literature evaluates the use of synchronous video visits for sexual-medicine care. A 2020 narrative review in Sexual Medicine Reviews concluded that the majority of sexual-medicine encounters can be conducted by telemedicine, with a framework for consent, documentation, coding, and HIPAA compliance [15]. A 2021 retrospective at a major academic sexual-medicine center documented stable racial and ethnic diversity in video-visit encounters during the COVID-19 expansion, with persistent access gaps among patients over 60, non-English speakers, and patients in broadband-poor areas [16].

A 2025 multi-country web-based survey across eight countries (n>1,800) by the International Sexual Health and Reproductive Health Consortium found that approximately 26% of pre-pandemic telemedicine non-users adopted it during COVID-19; sexual minorities adopted telemedicine at higher rates than the general sample; and approximately one-third of users reported a fair or poor experience, reinforcing that telehealth quality is uneven and that platform standards matter [17]. ACOG Committee Statement No. 20 (2025) frames telehealth as ethically appropriate for many women's-health services when licensure, consent, documentation, and equity standards are met, and is the most current professional guidance for OB/GYN remote prescribing [18]. The 5th International Consultation on Sexual Medicine (2025) endorses bremelanotide as a pharmacotherapy option within stepped HSDD care and lists nausea, flushing, headache, and contraindication in uncontrolled hypertension as the safety items to communicate [12].

Together, these sources establish the practice frame: bremelanotide can be evaluated and prescribed remotely by a state-licensed clinician using a synchronous video encounter, validated screeners (Decreased Sexual Desire Screener, FSFI-D, FSDS-DAO Item 13), a documented BP reading, an informed-consent step, an electronic prescription to a licensed dispensing pharmacy, and a planned follow-up [12][15][16][18].

## Exploratory and adjacent research

Two recent investigational lines deserve mention but are not part of the approved indication. A 2024 in vitro study reported that bremelanotide suppresses survivin expression and induces cell death in glioblastoma cell lines at concentrations non-toxic to normal cells, mediated through MC3R and MC4R — an exploratory finding unrelated to HSDD [21]. A 2025 Palatin press release on the Phase 2 BMT-801 study reported that low-dose bremelanotide co-administered with the dual GIP/GLP-1 agonist tirzepatide met its appetite-suppression endpoint and prevented post-tirzepatide weight regain over an 8-week trial — an investigational obesity application that is not approved [11].

Neither of these lines is currently a basis for clinical prescribing. They are reported here only because the bremelanotide research literature has begun to extend beyond the HSDD indication, and a serious editorial reference should note where the science is heading without conflating it with approved use.

---

An independent editorial digest of peer-reviewed literature and regulatory documents on the bremelanotide telehealth pathway — not a clinic, not a pharmacy, not medical advice.